Form 4: Atea Pharmaceuticals Director Bruno Lucidi Reports Significant Equity Changes Including RSU Vesting and New Option Grants

Atea Pharmaceuticals, Inc. Director Bruno Lucidi reported the vesting of 29,600 restricted stock units into common stock and the grant of new restricted stock units and stock options, increasing his beneficial ownership.

Summary

• Bruno Lucidi, a Director of Atea Pharmaceuticals, Inc. (AVIR), reported changes in his beneficial ownership of company securities via a Form 4 filing.
• On June 20, 2025, 29,600 restricted stock units (RSUs) vested and converted into 29,600 shares of common stock at a price of $0.00.
• Following this transaction, Mr. Lucidi's direct beneficial ownership of common stock increased to 112,750 shares.
• Concurrently, Mr. Lucidi was granted 29,600 new restricted stock units, which will vest in a single installment on the earlier of the next annual meeting or the first anniversary of the grant date (June 20, 2026), subject to continued service.
• He also received a grant of 41,200 stock options with an exercise price of $3.25 per share and an expiration date of June 19, 2035.
• These options will vest in 12 substantially equal monthly installments, becoming fully vested on June 20, 2026, contingent on his continued service.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates continued alignment of a director's interests with the company through equity compensation, which is a standard and expected practice.

Positives

• Director Bruno Lucidi's beneficial ownership of Atea Pharmaceuticals common stock increased to 112,750 shares following the vesting of restricted stock units.
• The grant of 29,600 new restricted stock units and 41,200 stock options aligns the director's interests with long-term shareholder value.

Negatives

• No negative information was reported in this Form 4 filing.

Risks

• No specific risks were mentioned in this Form 4 filing.

Future Outlook

The newly granted restricted stock units are set to vest in a single installment on the earlier of the next annual meeting or the first anniversary of the grant date (June 20, 2026). The newly granted stock options will vest in 12 substantially equal monthly installments, becoming fully vested on the first anniversary of the grant date (June 20, 2026). Both vesting schedules are subject to the reporting person's continued service.

Industry Context

It is standard practice in the biotechnology and pharmaceutical industries for directors and executives to receive equity-based compensation, such as restricted stock units and stock options, to align their interests with the company's long-term performance and shareholder value. This filing reflects a routine compensation event for a director.

Stakeholder Impact

• Shareholders: The increase in director's beneficial ownership and the grant of new equity awards align the director's interests with shareholders, potentially fostering long-term value creation.

Next Steps

• The new restricted stock units are expected to vest on the earlier of the next annual meeting or June 20, 2026.
• The new stock options are expected to vest monthly over the next year, becoming fully vested by June 20, 2026.

Key Dates

Keywords

Atea Pharmaceuticals, AVIR, Bruno Lucidi, SEC Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership, Director Compensation